Ignite Creation Date:
2025-12-24 @ 2:09 PM
Ignite Modification Date:
2026-02-24 @ 12:13 AM
Study NCT ID:
NCT01825395
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2021-10-06
First Post:
2013-03-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Sponsor:
University of Colorado, Denver
Organization:
Study Overview
Official Title:
Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)
Status:
APPROVED_FOR_MARKETING
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
3 4-DAP
Brief Summary:
To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: